Previous 10 | Next 10 |
Viela Bio Wins FDA Approval for Autoimmune Treatment Viela Bio ( VIE ) reported that the FDA has given its nod for Uplizna or inebilizumab-cdon for treating adult patients suffering from neuromyelitis optica spectrum disorder who are anti-AQP4 antibody positive. It is estimated that near...
GAITHERSBURG, Md., June 11, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE) today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA TM (inebilizumab-cdon) for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-AQ...
The FDA approves Viela Bio's (NASDAQ: VIE ) Uplizna (inebilizumab-cdon) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who harbor an antibody called anti-aquaporin-4 (AQP4). More news on: Viela Bio, Inc., Healthcare stocks news, Stocks on the move, Re...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 05/13/2020. Please visit our Tracking Ole Andreas Halvorsen...
Viela Bio (NASDAQ: VIE ) has priced its public offering of 3.6M common shares at $47.00/share, for expected gross proceeds of ~$169M. More news on: Viela Bio, Inc., Healthcare stocks news, , Read more ...
GAITHERSBURG, Md., May 27, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common st...
Viela Bio (NASDAQ: VIE ) intends to offer and sell 3M common shares in a public offering. More news on: Viela Bio, Inc., Healthcare stocks news, , Read more ...
GAITHERSBURG, Md., May 26, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced that it intends to offer and sell, subject to market and other conditions, 3,0...
Image source: The Motley Fool. Viela Bio Inc (NASDAQ: VIE) Q1 2020 Earnings Call May 13, 2020 , 5:00 p.m. ET Operator Continue reading
Viela Bio, Inc. (VIE) Q1 2020 Earnings Conference Call May 13, 2020 17:00 ET Company Participants Mitchell Chan - Chief Financial Officer Bing Yao - Chairman & Chief Executive Officer Bill Ragatz - Vice President, Head of Commercial Jorn Drappa - Chief Medical Officer &...
News, Short Squeeze, Breakout and More Instantly...
> A three-year partnership that aligns with Veolia’s mission to support organizations and industries that want to become more environmentally sustainable > Veolia will start with focusing on improving waste collection, increasing recycling percentages, providing sustainable w...
Clean Earth will partner with Veolia North America on a five-year agreement to provide guaranteed incineration capacity in a new state-of-the-art waste treatment facility in Gum Springs, Ark. The agreement provides reliable, predictable, safe, and efficient waste disposal for Clean Ea...
The array will produce over 250 million kilowatt hours of electricity – enough to power 25,000 homes – and offset carbon output by 105,000 tons over the next 25 years, making it the only hazardous waste treatment facility in U.S. to be fully energy self-sufficient Veolia N...